Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.
van Zeijl MCT, van Breeschoten J, de Wreede LC, Wouters MWJM, Hilarius DL, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MA, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Suijkerbuijk KPM, Haanen JBAG, van den Eertwegh AJM. van Zeijl MCT, et al. Among authors: kapiteijn e. J Immunother. 2023 Jun 1;46(5):197-204. doi: 10.1097/CJI.0000000000000468. Epub 2023 Apr 28. J Immunother. 2023. PMID: 37103470 Clinical Trial.
Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
van Dijk EH, van Herpen CM, Marinkovic M, Haanen JB, Amundson D, Luyten GP, Jager MJ, Kapiteijn EH, Keunen JE, Adamus G, Boon CJ. van Dijk EH, et al. Among authors: kapiteijn eh. Ophthalmology. 2015 Sep;122(9):1907-16. doi: 10.1016/j.ophtha.2015.05.027. Epub 2015 Jun 26. Ophthalmology. 2015. PMID: 26123090 Clinical Trial.
Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.
van der Kooij MK, Joosse A, Speetjens FM, Hospers GA, Bisschop C, de Groot JW, Koornstra R, Blank CU, Kapiteijn E. van der Kooij MK, et al. Among authors: kapiteijn e. Acta Oncol. 2017 Jan;56(1):101-103. doi: 10.1080/0284186X.2016.1260773. Epub 2016 Dec 2. Acta Oncol. 2017. PMID: 27911126 No abstract available.
Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.
Melief SM, Visconti VV, Visser M, van Diepen M, Kapiteijn EH, van den Berg JH, Haanen JB, Smit VT, Oosting J, van der Burg SH, Verdegaal EM. Melief SM, et al. Among authors: kapiteijn eh. Cancer Immunol Res. 2017 Feb;5(2):170-179. doi: 10.1158/2326-6066.CIR-16-0288. Epub 2017 Jan 10. Cancer Immunol Res. 2017. PMID: 28073773
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.
de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D. de Moel EC, et al. Among authors: kapiteijn eh. Cancer Immunol Res. 2019 Jan;7(1):6-11. doi: 10.1158/2326-6066.CIR-18-0245. Epub 2018 Nov 13. Cancer Immunol Res. 2019. PMID: 30425107
Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study.
van Zeijl MCT, Boer FL, van Poelgeest MIE, van den Eertwegh AJM, Wouters MWJM, de Wreede LC, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Kapiteijn EHW, Haanen JBAG. van Zeijl MCT, et al. Among authors: kapiteijn ehw. Eur J Cancer. 2020 Sep;137:127-135. doi: 10.1016/j.ejca.2020.05.021. Epub 2020 Aug 4. Eur J Cancer. 2020. PMID: 32763783
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.
Boekhout AH, Rogiers A, Jozwiak K, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JWB, Aarts MJB, Kapiteijn E, Ten Tije AJ, Piersma D, Vreugdenhil G, van der Veldt AA, Suijkerbuijk KPM, Rozeman EA, Neyns B, Janssen KJ, van de Poll-Franse LV, Blank CU. Boekhout AH, et al. Among authors: kapiteijn e. Acta Oncol. 2021 Jan;60(1):69-77. doi: 10.1080/0284186X.2020.1818823. Epub 2020 Sep 14. Acta Oncol. 2021. PMID: 32924708
Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry.
van Zeijl MCT, de Wreede LC, van den Eertwegh AJM, Wouters MWJM, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven JJM, Haanen JBAG. van Zeijl MCT, et al. Among authors: kapiteijn e. Eur J Cancer. 2021 Feb;144:242-251. doi: 10.1016/j.ejca.2020.11.028. Epub 2020 Dec 26. Eur J Cancer. 2021. PMID: 33373869
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
Mulder EEAP, de Joode K, Litière S, Ten Tije AJ, Suijkerbuijk KPM, Boers-Sonderen MJ, Hospers GAP, de Groot JWB, van den Eertwegh AJM, Aarts MJB, Piersma D, van Rijn RS, Kapiteijn E, Vreugdenhil G, van den Berkmortel FWPJ, Hoop EO, Franken MG, Ryll B, Rutkowski P, Sleijfer S, Haanen JBAG, van der Veldt AAM. Mulder EEAP, et al. Among authors: kapiteijn e. BMC Cancer. 2021 Mar 25;21(1):323. doi: 10.1186/s12885-021-08018-w. BMC Cancer. 2021. PMID: 33765967 Free PMC article.
187 results